Volume 40,
Issue 12,
2012
-
扉・目次
-
-
Source:
薬理と治療 40巻12号, 1043-1044 (2012);
View Description
Hide Description
-
DRUG PROFILE SERIES
-
-
Source:
薬理と治療 40巻12号, 1047-1071 (2012);
View Description
Hide Description
-
ORIGINAL ARTICLES
-
-
Source:
薬理と治療 40巻12号, 1073-1078 (2012);
View Description
Hide Description
The objective of this retrospective study was to investigate the efficay of antiemetic therapy with palonosetron and aprepitant for the treatment of nausea and vomiting induced by cisplatin-based highly emetogenic chemotherapy. This study included 119 cancer patients who received cisplatin(≧50mg/m2)-based chemotherapy between September 2008 and March 2011. According to the antiemetics administered, the patients were divided into the following 3 groups:GD(granisetron+dexamethasone;n=47), GAD(granisetron+aprepitant+dexamethasone;n=37)and PAD(palonosetron+aprepitant+dexamethasone;n=35).“Complete response(CR)defined as“no-emesis”and“no-rescue medication”, and“no-significant nausea”during the overall phase(0-120 h after cisplatin injection)of the first chemotherapy cycle were evaluated. CR of patients in the GAD(83.8%;odds ratio[OR], 5.85;95% confidence interval[CI], 1.79-19.08;p<0.01)and PAD groups(82.9%;OR, 4.45;95% CI, 1.46-13.63;p<0.01)was significantly higher than that of patients in the GD group(55.3%). The percentage of patients with“no-significant nausea”was significantly higher in the PAD group(80.0%;OR, 9.17;95% CI, 3.18-26.44;p<0.001)than in the GD group(29.8%).The degree of improvement of CR and “no-significant nausea” seemed to be higher in the female patients than in the male patients. In conclusion, palonosetron and aprepitant seem to improve CR and“no-significant nausea”in patients receiving cisplatin-based chemotherapy. Moreover, the addition of palonosetron and aprepitant may be more beneficial to female than to male patients.
-
Source:
薬理と治療 40巻12号, 1081-1088 (2012);
View Description
Hide Description
Objectives The use of generic medicines is generally recommended for reducing medical costs. However, many doctors and pharmacists do not trust the quality, efficacy and safety of some generic medicines. Loxonin containing loxoprofen sodium is widely used as an antipyretics analgesic, and Lobu is the generic form of Loxonin. The pharmaceutical and therapeutic equivalence of Lobu was compared to Loxonin. Methods The dissolution rate of loxoprofen sodium from Lobu was compared to that of Loxonin. In addition, clinical data of the patients treated with Lobu in Fukuoka Memorial Hospital was compared to those treated with Loxonin in Fukuoka University Chikushi Hospital. The number of patients treated with Lobu and Loxonin was 76 and 79, and the mean age was 45.8 years old and 47.5 years old, respectively. Results Lobu did not meet the standard of the dissolution test of loxoprofen sodium at a pH of 1.2. However, the analgesic effect of Lobu on patients undergone orthopedic surgery was equal to that of Loxonin. In addition, severe hematopoietic injury, hepatic dysfunction, or renal dysfunction were not observed during Lobu treatment. Conclusions Although Lobu is not 100% pharmaceutically equivalent to Loxonin, the efficacy and safety are considered to be equivalent to Loxonin.